22/09/2021 – AB Science today announced that its clinical trial with AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML) has been approved by Health Canada Download PDF Post navigationPreviousPrevious post:Abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of NeurologyNextNext post:AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 studyRelated PostsAB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus29 November 2021AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia22 November 2021AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS18 November 2021AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)18 October 2021AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)4 October 2021Revenues for the first half of 2021 and update on AB Science’s activities30 September 2021
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus29 November 2021
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia22 November 2021
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS18 November 2021
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)18 October 2021
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)4 October 2021
